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Abstract
Background: Ependymal tumors with oligodendroglioma like clear cells have 
never been reported from Pakistan. We aimed to see the features and outcomes 
of this rare entity.
Methods: It was retrospective cohort conducted at the Department of Neurosurgery, 
Aga Khan University from 2003 to 2013. The medical records and radiology of 
patients with proven histopathology were reviewed. Analysis was done on SPSS 20.
Results: Eleven cases of ependymal tumors with clear cells were found, which 
equated to 1.5% of the total tumor burden in 11 years. The median age was 
49 years. Most common presenting symptom was headache 54.5%. Out of 11 
patients, 9 patients had a supratentorial tumor. Magnetic resonance imaging 
showed hypointense signals on T1 and hyperintense signals on T2‑weighted 
images in all cases. Contrast enhancement was found in 9 patients (77.8%), 
necrosis and hemorrhage was found in 4 (36%) and 3 (27%) patients, respectively. 
Immunohistochemistry showed glial fibrillary acidic protein and epithelial membrane 
antigen positivity in all cases. Ki‑67 showed high proliferative index in 6 patients. 
According to the World Health Organization grading of ependymal tumors, 2 
patients had Grade II tumors, and 9 patients had Grade III tumors with clear 
cells. Gross total resection was achieved in 6 (54.5%) and subtotal resection in 5 
patients (45.4%). Recurrence was observed in 9 patients. Six patients died of the 
disease. Median progression‑free survival and overall survival was 8 months and 
10 months, respectively.
Conclusion: Ependymal tumors with clear cells presented more commonly in 
Grade III lesions and were more aggressive in behavior with poorer outcome 
compared to similar studies.
Key Words: Anaplasia, clear cells, overall survival, progression‑free survival, 
supratentorial
INTRODUCTION
Ependymal tumors are rare neuroepithilial tumor which 
represent only 2–8% of all central nervous system (CNS) 
malignancies.[7] The World Health Organization (WHO) 
has classified ependymal tumors into: Subependymoma, 
myxopapillary ependymoma (WHO Grade I), ependymoma 
(WHO Grade II), and anaplastic ependymoma (WHO 
Grade III). Ependymoma (WHO Grade II) is further 
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subcategorized into cellular, clear cell, papillary, and 
tanycytic ependymoma.[10,20,26] Clear cell ependymoma 
(CCE) is a rare, relatively recent, and diagnostically 
challenging variant of ependymoma, which was included in 
the WHO classification of tumors in 1993.[19]
The literature has been scarce on this entity since it was 
first described in 1983.[16] CCE are mostly supratentorial 
in location. Other sites described in the literature include 
cervical and thoracic spinal cord, brain surface, medulla 
oblongata, fourth ventricle, and cerebellum.[2,3,8,15,17,18,26,31] 
Tumor cells display classic ependymal rosettes and 
perivascular pseudorosettes with an oligodendroglioma 
(ODG) like appearance with a clear perinuclear halo and 
immune reactivity, showing positivity for glial fibrillary 
acidic protein (GFAP) and epithelial membrane antigen 
(EMA).[8,10,15,22]
Grade II ependymoma undergo malignant transformation 
to Grade III and have lower rate of cure even with 
extensive resection, this is why although CCE is a 
variant of ependymoma Grade II, but most of the series 
published to date, show presence of clear cells more in 
histologically proven anaplastic ependymoma Grade III 
than Grade II.[26] CCEs have a tendency to be aggressive 
despite therapy. It is important to distinguish this entity 
from ODG, central neurocytoma, clear cell carcinoma, 
and hemangioblastoma mainly because the treatment 
and prognosis of each differ significantly.[10,12] It is also 
worth mentioning about some extremely rare entities 
of ependymal tumors including giant cell ependymoma, 
ependymoma with lipomatous differentiation, signet ring 
cell ependymoma, and melanotic ependymoma as they 
have also been described in the literature.[1,4,9,10,12]
To the best of author’s knowledge, there is no report on 
the behavior and outcome of disease from this country 
and hence we aimed to describe the frequency, clinical, 
radiological, surgical and histopathological aspects, and 
outcome of all ependymal tumors containing ODG 
like clear cells including WHO Grade II and Grade III 
tumors, managed at our institution along with a review of 
available literature.
MATERIALS AND METHODS
This is a retrospective case series of all ependymal tumors 
containing ODG like clear cells, surgically treated at 
the section of neurosurgery, Department of Surgery, Aga 
Khan University, Karachi, Pakistan from January 2003 
to December 2013. Medical records of all primary brain 
neoplasms treated during this period were retrieved from 
the electronic database of the hospital using ICD code 
190.0–191.9.
Data were systematically collected on a structured 
proforma, which included patient demographics, presenting 
complaints, duration of symptoms in months, Karnofsky 
performance score (KPS), radiology, course of treatment 
including surgery, adjuvant therapy (chemotherapy [CMT] 
and radiotherapy [RXT]), progression‑free survival (PFS), 
and recurrence as suggested by interval 3 monthly magnetic 
resonance imaging (MRI) of brain and overall survival (OS).
Information about aforementioned aspects were obtained 
from patient initial out patient Department (OPD) notes, 
initial assessment forms, progress notes, operative notes 
retrieved through medical record office, and telephonic 
calls to patients/attendants were applicable. MRI and 
computerized tomography (CT) scans of brain were 
reviewed on picture archiving and communication system 
of the hospital (PACS) for the location of the tumor to 
lobe, initial size, and feature specific to tumors such as 
contrast enhancement, appearance on T1‑weighted and 
T2‑weighted images, and associated characteristics such 
as presence of mass effect, cystic, hemorrhagic, or necrotic 
areas were obtained. The histopathology slides were 
retrieved and reviewed and all the cases that contained the 
features of ependymal tumors with ODG like clear cells 
were described by a consultant histopathologist for features 
including the WHO grade and immunohistochemical 
stains for the purpose of current study.
Gross total resection (GTR) was defined as excision of 
more than 95% of tumor and subtotal resection (STR) 
was defined as excision of <95% tumor.
The data were recorded and analyzed using IBM‑SPSS 
statistics 20 (SPSS 20, IBM, Armonk, NY, United States 
of America). Median was calculated for continuous 
variables and frequencies and proportions were calculated 
for categorical variables. Kaplan–Meier curve analysis was 
done for PFS and OS.
RESULTS
In an 11 year period from January 1, 2003, to December 
31, 2013, there were a total of 727 cases of primary 
CNS tumors that were treated surgically at the Aga 
Khan University, of which there were 51 (7%) cases of 
ependymal tumors. Histopathologically proven clear cells 
were found in 11 (1.5%) cases.
The results showing age, gender, presenting symptoms, 
and duration of symptoms are summarized in Table 1.
Imaging features
A total of 10 patients had MRI done, 1 patient had CT 
scans done for diagnosis and progression of the disease 
secondary to a cardiac pacemaker. The MRI features of 
all the patients in the series are summarized in Table 2 
[Figure 1].
Histopathology
The histopathological assessment showed diffuse sheets 
of spindle to epithelioid neoplastic cells embedded 
within a fibrillary background in all cases. The 
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perivascular pseudorosettes were frequent in 8 cases and 
focal in 3. Clear ODG like cells, suggested by having 
moderate amount of clear to eosinophilic cytoplasm, 
moderate pleomorphic, round to oval nuclei surrounded 
by perinuclear halo were found in few areas in 5 cases, 
whereas more frequently in 6 cases. Increased cellularity, 
occasionally prominent nucleoli, atypical mitotic figures, 
necrosis, and microvascular proliferation was seen in 
9 out of 11 patients. Minigemistocytes were seen in 2 
cases.
Immunohistochemistry showed that the tumor was GFAP 
and EMA positive in all cases (100%). Ki‑67 showed low 
proliferative index in 5 patients and high proliferative 
index in 6 patients. WHO class was Grade II in 2 patients 
and Grade III in 9 patients [Figure 2].
Treatment
Each case was discussed in the multidisciplinary tumor 
board meeting comprising of consultant neurosurgeons, 
radiologists, histopathologists, radio‑oncologists, senior 
nurses, and medical oncologists. At the time of writing 
this article we are following the National Comprehensive 
Cancer Network (NCCN) USA, clinical practice 
guidelines in oncology for CNS cancers for the treatment 
of adult intracranial ependymoma.[24]
All 11 patients primarily underwent surgery, out of 
these 7 patients received concomitant external beam 
fractionated radiotherapy (EBRT) only, 3 patients 
received concomitant EBRT and CMT/temozolomide 
(TMZ), and 1 patient received no therapy (patient’s 
wish) after initial diagnosis.
Recurrence was observed in 9 patients, 1 patient had no 
evidence of disease (NED) until writing this article, and 1 
patient refused for further investigation or treatment. Out 
of 9 patients who had recurrence of disease, 6 patients did 
not have further treatment. In the remaining 3 patients 
repeat surgery was performed, of which 2 patients further 
received re‑RXT and CMT (1 patient was given cisplatin 
plus etoposide 6 cycles, the other patient was given TMZ 
Table 1: Age, gender, presenting symptoms, and duration of symptoms of all the patients in the series
Patient Age (year) Sex Presenting symptoms KPS at 
presentation
Symptoms 
duration (weeks)
1 40 Male Dizziness, GTCS, slowed speech >70 24
2 38 Male Headaches, right sided weakness <70 24
3 55 Male Headache, decreased appetite, lethargy, confusion >70 8
4 24 Female Headache, vomiting >70 12
5 40 Female GTCS, left hemiparesis >70 1.6
6 47 Male Headache, GTCS, right sided weakness <70 18
7 72 Male Hemianopia >70 4
8 49 Female Pins and needles >70 12
9 62 Male Headache, vertigo, aural fullness, amnesia >70 8
10 62 Female Seizures, left sided hemiparesis <70 1.5
11 65 Male Slurred speech, headache >70 1
GTCS: Generalized tonic clonic seizures, KPS: Karnofsky performance score
Table 2: MRI characteristics of all the patients in the series
Patient Radiological/MRI characteristics
Location Initial size (cm) Cystic Hemorrhagic Necrosis C++ Mass 
effect
Signal relative 
to cortex T1
Signal relative 
to cortex T2
1 Right frontotemporal 6.7×7.0×6.0 No No No No Yes Hypointense Hyperintense
2 Left parietal 6.2×6.0×5.2 Yes No No Yes Yes Hypointense Hyperintense
3 Right temporoparietal 6.5×4.3×5.8 Yes No Yes Yes Yes Hypointense to isointense Hyperintense
4 Right frontotemporal 7.3×4.1×5.7 Yes No No No Yes Hypointense to isointense Hyperintense
5 Right parietal 3.3×4.6×3.5 No No No No No Hypointense Hyperintense
6 Left occipital + 
corpus callosum
7.8×3.2×5.2
3.1×1.7×2.3
Yes No Yes Yes Yes Hypointense Hyperintense
7 Left occipital 2.3×2.2×2.7 Yes Yes Yes Yes No Isointense Hyperintense
8 Right temporoparietal NA NA NA NA NA NA NA NA
9 Right parietal 2.0×2.9×4.4 Yes Yes Yes Yes No Isointense to hyperintense Hyperintense
10 Right parietal 3.5×3.0×2.8 No Yes No Yes No Hypointense Hyperintense
11 Right temporal 4.0×6.2×3.0 Yes No No Yes No Hypointense Hyperintense
C++: Contrast enhancement, MRI: Magnetic resonance imaging, NA: Not available
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6 cycles), whereas 1 patient received re‑RXT alone.
Six patients expired of the disease. One patient refused 
for any further treatment post‑GTR and expired 
5 months after the primary surgery. Four underwent 
EBRT postprimary surgery, one of them remained 
progression free for almost 28 months postprimary 
surgery, underwent repeat surgery twice within an interval 
of 5 months followed by TMZ and re‑RXT, and she 
expired on 52 months postprimary surgery. Three more 
underwent EBRT but had progression of disease, 2 
patients underwent concomitant CMT (one with TMZ 
6 cycles and other with cisplatin and etoposide 6 cycles) 
along with re‑RXT. The patient with TMZ + re‑RXT 
was dead of the disease 10 months postprimary surgery 
and patient with cisplatin plus etoposide + re‑RXT had 
metastasis to corpus callosum, thalamus and had dural 
deposits, he was lost to follow‑up at 19 months from 
primary surgery.
Currently, 4 patients are under follow‑up until writing 
this article. One patient underwent STR, followed by 
concomitant TMZ, and EBRT had reduction in residual 
size and has no evidence of progression 10 months 
from the surgery. The second patient underwent GTR 
followed by EBRT in Italy, he remained progression 
free for 12 months however, the tumor recurred, he 
refused further treatment, he is alive on 67 weeks since 
his primary surgery; however, currently he is bedridden, 
dependent for all his activities, KPS 20. The third patient 
STR, her initial histology shows features of ODG, she was 
followed by TMZ and EBRT; however, her tumor recurred 
at 8 month postsurgery, she again underwent STR, this 
time the histopathology showed CCE, she underwent 
re‑RXT, currently she has NED for 10 months post 
re‑surgery, total 18 months from first surgery. The fourth 
patient underwent GTR + EBRT and had recurrence at 
3 months and currently has stable disease at 5 months.
The median PFS was 8 months ranging from minimum 
3 months and maximum 28 months, and the median 
OS was 10 months (range 6 months–52 months) after 
primary surgery. The extent of resection, intraoperative 
tumor findings, initial diagnosis, treatment given, 
recurrence, PFS, and OS are summarized in Table 3 
[Figure 3].
DISCUSSION
CCE is considered to be Grade II supratentorial and 
extraventricular tumor, occurring predominantly in young 
patients.[34] The histopathological classification described 
by WHO has defined CCE as a variant of ependymoma 
Grade II, however, we have 9 out of 11 cases showing the 
ependymal clear cells in anaplastic ependymoma Grade 
III instead of ependymoma Grade II. The literature 
has also described more cases of ODG like clear cells 
present in anaplastic ependymoma Grade III rather than 
ependymoma Grade II.[6,8,13,22,28,30]
Interestingly, the median age of our series was 49 years 
(age range 24–72 years). This was significantly different 
from the cohorts of Fouladi et al.[8] Rickert et al.[30] the 
two biggest cohorts on the subject who have reported this 
disease in pediatric age group along with others who have 
also reported this disease in the pediatric age group.[11,27,28] 
Similar to our age group, we found comparable cohorts of 
Kawano et al., Min and Scheithauer[16,23] along with few 
case reports from others.[3,5,14,31‑33]
Figure 1: Magnetic resonance imaging scans of patient 
number 3.(a) T1-weighted magnetic resonance image of patient 3, 
showing hypo to isointense tumor in right temporoparietal cortex 
with compression and near effacement of right lateral ventricle, 
subfalcine herniation, and midline shift. (b) T1 with gadolinium 
of the same patient showing subtle peripheral ring enhancement 
and loculations.(c) T2-weighted image of the same patient showing 
cystic areas with solid component displaying hyperintense signals
b
c
a
Figure 2: Histopathological slides of the patients in the series.
(a) H and E stain of patient 1, showing clear cell morphology.
(b) H and E stain of patient 1, showing perivascular pseudorosettes.
(c) Slide displaying epithelial membrane antigen positivity in 
patient number 2.(d) Slide showing 10–15% (high) Ki-67 positivity 
in patient number 5
b
dc
a
 SNI: Neuro-Oncology 2015,  Vol 6, Suppl 23 - A Supplement to Surgical Neurology International
S587
The treatment of intracranial ependymoma as suggested 
by NCCN guidelines 2014[24,25] include GTR if feasible, 
followed by MRI spine for drop mets if histopathology is 
suggestive of anaplastic ependymoma Grade III, followed 
by limited EBRT 54–59.4 Gy, in 1.8–2.0 Gy fractions. 
In case of recurrence, re‑resection is recommended 
if resectable followed by EBRT if no prior RXT is 
received and in case if prior RXT is given, then consider 
re‑irradiation or CMT with platinum‑based, etoposide, 
nitrosourea, bevacizumab, or palliation. The regimen of 
ODG necessitates the use of adjuvant TMZ with EBRT, 
45–54 Gy in case of low‑grade gliomas (Grade I and II), 
Table 3: Lists the EOR, gross morphology, initial diagnosis, treatment, and outcome
Patient EOR Intraoperative gross tumor 
morphology
Initial 
diagnosis
Recurrence PFS 
(months)
Overall therapy Overall survival/
outcome (months)
1 GTR Soft, vascular, adherent to vessels CCE Local 12 GTR + EBRT 60 Gy 30 fractions SD at 16 months
2 GTR Hard, vascular, sclerotic ODG Spread to 
corpus callosum, 
thalamus, dural 
deposits
4 Surgery + EBRT 54 Gy in 30 
fractions outside our hospital
GTR in our hospital + cisplatin 
+ etoposide 6 cycles + 
re‑radiotherapy
Lost to follow‑up 
4 months after 
second surgery
3 GTR Soft, yellowish, moderately vascular CCE No therapy DOD at 6 months
4 STR Solid cum cystic, yellowish, 
moderately vascular
CCE None 10 STR + TMZ + EBRT 60 Gy 
30 fractions
NED at 10 months
5 STR
STR
Soft, mildly vascular (surgery 1)
Soft, mildly vascular, easily separable 
(surgery 2)
ODG Local 8 STR + TMZ + EBRT 60 Gy 
30 fractions
STR + re‑radiotherapy
SD at 18 months 
post first 
symptoms
6 STR Grayish white, moderately vascular CCE Local 5 STR + TMZ + EBRT 60 Gy 
30 fractions
DOD at 10 months
7 GTR Soft, grayish white, moderately vascular CCE Local 6 GTR + EBRT 60 Gy 30 fractions DOD 10 months
8 STR
STR
STR
Soft, grayish yellow, moderately 
vascular, cystic (surgery 1)
Vascular, cyst (surgery 2 and 3)
ODG Local 28 STR + EBRT 54 Gy 30 fractions
STR + CMT (undocumented) + 
re‑radiotherapy
STR
DOD at 52 months
9 GTR Soft, moderately vascular with 
thrombosed vessels, adherent to dura
CCE Local 5 GTR + EBRT 54 Gy 30 fractions DOD at 10 months
10 GTR Soft, vascular with thrombosed vessels CCE Local 3 GTR + EBRT 60 Gy 30 fractions SD at 5 months
11 STR Soft, yellowish, moderately vascular CCE Frontal, 
periventricular, 
posterior fossa
8 STR + EBRT 54 Gy 30 fractions DOD at 9 months
CCE – Ependymal tumor with ODG like clear cells. GTR: Gross total resection, STR: Subtotal resection, ODG: Oligodendroglioma, EBRT: External beam fractionated radiotherapy, 
TMZ: Temozolomide, CMT: Chemotherapy, DOD: Dead of disease, NED: No evidence of disease, SD: Stable disease, KPS: Karnofsky performance scale, EOR: Extent of resection, 
CCE: Clear cell ependymoma
Figure 3: Kaplan–Meir curves for progression-free survival and overall survival.(a) Kaplan–Meir curve showing progression-free survival in 
months in the series.(b) Kaplan–Meir curve showing overall survival in months in the series
ba
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and recommended 60 Gy in case of high‑grade gliomas 
(Grade III and IV).
The clinical presentation is similar to that reported in 
other studies.[8] The primary tumor site was supratentorial 
in 9 out of 10 patients of Fouladi et al. and all cases in 
Min and Scheithauer[23] case series. Rickert et al.[30] 
case series of 13 CCE also concluded similar location 
with 12 CCE in supratentorial and 1 in infratentorial 
compartment. Most case series have described the tumor 
in supratentorial compartment.[22,31] However, Kawano’s 
second series showed all 6 cases in cerebellum, whereas 
his first series showed 2 of 4 cases in cerebellum. 
Furthermore, occipital CCE has also been reported in 
the literature[16,17,27,28] and to add on Amatya et al.[3] 
reported CCE in medulla oblongata, Katoh et al.[15] 
reported a case in the fourth ventricle. None of our 
patients had the tumor in cerebellum, fourth ventricle, or 
medulla oblongata. Kurt et al. suggested that there is no 
significant difference in OS of supratentorial CCE and 
infratentorial CCE.[21]
With respect to radiological features, Fouladi et al.[8] 
described most cases to be isointense on both T1‑ and 
T2‑weighted images. Enhancement was present in all 
cases, and most had associated cysts with enhancing 
walls. Fifty percentage of the tumors had associated 
hemorrhage, 70% tumors had regions of necrosis, and 
most had mass effect. Hayashi et al. described the tumor 
as having calcification on CT scan brain and cystic cum 
solid hypo‑ to iso‑intense contrast enhancing tumor on 
T1 and hyperintense tumor on T2‑weighted images of 
MRI.[11] Sato et al. also observed hypointense signals on 
T1, contrast enhancement, and cystic component.[31]
In our study, we observed hypointense signals on T1 and 
hyperintense signals on T2‑weighted images, associated 
cysts, and enhancement in 9 out of 11 patients, mass 
effect was present in 5 patients; however, necrosis and 
hemorrhage were present in 4 and 3 patients, respectively.
Similar findings were reported by other authors.[3,13,15,22]
The gross intraoperative examination of the tumor is 
rarely reported in the literature, Jain et al.[13] reported 
one of the cases as soft and vascular and the other 
case as fleshy and vascular, Amatya et al.[3] described 
the tumor as having cystic and nodular parts, cystic 
was well circumscribed purplish red and nodular was 
hard in consistency, Lee et al. described their finding as 
yellowish brown, soft, friable tumor,[22] Sato et al. also 
had yellow‑grayish tumor.[31] This is comparable to gross 
examination of our tumors most of which were also 
yellowish brown, soft, moderately vascular, and having 
solid and cystic components.
WHO has not clearly defined the histological criteria to 
classify the tumor as CCE with respect to the percentage 
of ODG like clear cells and ependymoma like areas 
present. Fouladi et al.[8] suggested that features of clear 
cells varied from focal to diffuse with focal necrosis 
in all patients, in Rickert et al. series clear cells varied 
from focal to diffuse.[30] Others also had reported sheets 
of clear cells, focal perivascular pseudorosettes, whereas 
true ependymal canals and rosettes were absent.[9,15,19] 
Kurt et al. declared MIB 1 (Ki‑67) as the most important 
prognostic factor in defining anaplasia in ependymoma.[21]
The median PFS of our study was 8 ± 6.7 months 
postsurgery, and median OS was 10 ± 14 months 
postsurgery. This was significantly different from the 
cohorts of Kawano et al.,[16] Min and Scheithauer,[23] 
Fouladi et al.,[8] and Kawano et al.[16] first 2 cases were 
dead of disease in 52 and 20 months, other cases 
survived for more than 100 months. Rickert et al.[30] 
survival (mean >52 months) was also better than our 
cohort. Fouladi et al.[8] 5 years PFS was 34 ± 20% and 
OS 75 ± 19%. None of our patients survived up to 
5 years. Maximum PFS was 28 months in 1 patient, and 
maximum OS was 52 months in the same patient. To our 
comparison is a series of 3 cases by Jain D,[13] from India, 
1 patient lost to follow‑up at 4 months, 1 died of disease 
at 21, and other at 24 months. This may suggest that in 
this part of the world India and Pakistan, this tumor is 
comparatively more aggressive than in Japan, the United 
States of America, and Australia.
Our cohort highlights the significant amount of 
misdiagnosis and confusion in diagnosing CCE; this 
highlights the use of more precise immunohistochemical 
stains and cytogenetic testing to confirm the diagnosis. 
Preusser et al. described OLIG‑2 an additional 
immunohistochemical marker to differentiate between 
ODG and CCE.[29] Fouladi et al. showed deletion of 
CEP18 and DAL1 and polysomy of 1p, 19q, and NF2 
loci in CCE.[8] Rickert et al. showed genomic aberration 
at chromosome 9 in ependymoma Grade II, and +1q, 
+13q, and −9, −3, −22 in anaplastic ependymoma 
Grade III.[30] Because of financial and resource constraints 
we were unable to perform these tests and comment on 
these aspects of the tumor at this moment, however, we 
aspire to study and comment on cytogenetics in near 
future.
Our limitation was a small sample size, a single institution 
data, and a retrospective study design. This is the first 
report from Pakistan addressing a detailed description 
of clinical, radiological, and histopathological features of 
this tumor.
CONCLUSION
Ependymal tumors mixed with ODG like clear 
cells constituted only 1.5% of all the CNS tumors 
presenting at our institute over past 11 years. A 
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correct histopathological diagnosis aided with precise 
immunohistochemical stains and cytogenetic testing is 
critical for appropriate management and better outcome. 
In contrast to previous reports, we found majority of our 
patients (9 out of 11) had Grade III ependymal tumor 
with clear cells which may suggest a more aggressive 
disease on presentation, which may account for a poorer 
outcome in our cohort. However, our results were 
concordant with results reported from India, suggesting a 
possibility of more aggressive disease in this region.
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